Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-38.63	-72.7	-135.35	-108.5	-73.96
Depreciation & Amortization	8.36	8.12	6.22	3.75	2.13
Stock-Based Compensation	18.87	18.13	16.67	11.66	5.2
Other Adjustments	-2.2	-2.95	-3.81	2.76	0.98
Change in Receivables	-11.43	0.33	1.9	-0.19	-0.7
Changes in Accounts Payable	-13.71	6.25	5.76	-0.74	6.59
Changes in Accrued Expenses	7.85	4.18	3.56	1.03	1.11
Changes in Unearned Revenue	7.52	83.38	50	-	-
Changes in Other Operating Activities	0.57	-2.75	11.25	-2.23	-0.71
Operating Cash Flow	-22.8	42	-43.8	-92.47	-59.36
Capital Expenditures	-4.7	-3.99	-19.04	-12.91	-9.73
Sale of Property, Plant & Equipment	-	-	0.06	0.11	0.08
Purchases of Investments	-376.68	-230.36	-103.15	-384.42	-
Proceeds from Sale of Investments	279.54	189.9	210.93	178	-
Investing Cash Flow	-101.83	-44.45	88.8	-219.22	-9.65
Issuance of Common Stock	30.71	99.53	27.61	20.83	237.9
Net Common Stock Issued (Repurchased)	30.71	99.53	27.61	20.83	237.9
Issuance of Preferred Stock	-	-	-	-	143
Net Preferred Stock Issued (Repurchased)	-	-	-	-	143
Other Financing Activities	-0.36	-0.64	-0.12	-0.36	-3.34
Financing Cash Flow	30.35	98.89	27.49	20.47	377.56
Net Cash Flow	-94.28	96.44	72.49	-291.22	308.55
Free Cash Flow	-27.5	38.01	-62.84	-105.38	-69.1
FCF Margin	-22.23%	50.26%	-	-	-
Free Cash Flow Per Share	-0.33	0.51	-1.22	-2.23	-2.76
Levered Free Cash Flow	-32.73	22.5	-77.6	-119.61	-74.57
Unlevered Free Cash Flow	-46.82	11.11	-85.92	-123.5	-73.49

Updated Mar 17, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q